°³¿ä
À¯¹ßÀÎÀÚ(bacterial endocarditis)
|
À¯¹ßÀÎÀÚ |
¼¼ºÎ»çÇ× |
|
Native valve |
rheumatic heart disease |
mitral valve: most common site of infection |
|
congenital heart disease |
high pressure gradient¸¦ º¸ÀÌ´Â Áúȯ(VSD, pul. stenosis, TOF) |
|
calcific degenerative valve disease |
°í·É¿¡¼ ÈçÇÔ |
|
mitral valve prolapse |
echo¿¡¼ ¿ª·ù°¡ º¸À̰ųª, ûÁø»ó ÀâÀ½ÀÌ µé¸®¸é À§Ç輺 Áõ°¡ |
|
history of IV drug use |
right sided endocarditisÀÇ °¡Àå ÈçÇÑ ¿øÀÎ, Àç¹ßÀ²: 41% |
|
Prosthetic valve |
prosthetic heart valve |
ÆÇ¸·Ä¡È¯ÀÇ ½É°¢ÇÑ ÇÕº´Áõ |
|
history of endocarditis |
Çѹø °¨¿°µÈ valve´Â ºÒ±ÔÄ¢ÇÏ°Ô Ä¡·á°¡ µÇ¾î ´Ù½Ã À§ÇèÀÎÀÚ°¡ µÊ |
º´Å»ý¸®
Áõ»ó ¹ßÇö ¾à 1ÁÖÀÏ Àü¿¡ ´Ù¾çÇÑ ¼ö¼úÀû óġ(Ä¡°ú ½Ã¼ú, ¹æ±¤°æ, urethral dilatation, ERCP, esophageal dilatation)ÀÇ °á°ú·Î subclinical bacteremia°¡ ¼±Çà
sterile thrombus(¿Ü»ó, ¿°Áõ, abnormal turbulence°¡ ÀÖ´Â °÷¿¡ »ý±è)¿¡ microorganismÀÌ ºÙ°í, Áõ½ÄÇÏ¿© vegetationÀ» Çü¼º
¿øÀαÕ
|
À¯¹ßÀÎÀÚ |
¿øÀÎ±Õ |
|
Native valve endocarditis |
Streptococci°¡ ÈçÇÔ
¨ç Streptococcus viridans- most common
¨è Streptococcus bovis- GI malignancy¿Í ¿¬°ü |
|
IV drug abuse |
Staphylococcus |
|
Prosthetic valve endocarditis |
Coagulase negative staphylococcus(S. epidermis) |
|
long term indwelling IV catheter
immunosuppresed- ¾Ç¼ºÁ¾¾ç, AIDS, À̽Ä
IV drug use |
fungus(Candida, Aspergillus)
¨ç Á¾Á¾ »öÀüÀ» À¯¹ß
¨è Ç÷¾×¹è¾ç À½¼º: »öÀüÀÇ Á¶Á÷ÇÐÀû °Ë»ç¸¦ ÅëÇØ Áø´Ü |
HACEK group(haemophilus species, Actinobacillus, Cardiobacterium hominis, Eikenella, Kingella kingae)- ¹è¾çÀÌ Èûµç Á¾·ù·Î Ç÷¾×¹è¾ç À½¼º ½É³»¸·¿°À» ÀÏÀ¸Å´
ÀÓ»ó ¾ç»ó
|
ºÐ·ù |
¼¼ºÎ»çÇ× |
|
Classic triad |
fever |
IV drug user¿¡°Ô¼ ´õ ÈçÇÔ |
|
anemia |
|
|
heart murmur |
´ëºÎºÐ¿¡¼ Á¸Àç(15% Á¤µµ°¡ ¾ø°í, Ãʱ⿡´Â ´õ ¸¹Àº ¼ö°¡ ¾øÀ½)
IV drug userÀÇ °æ¿ì <35%¿¡¼ Á¸Àç<- right sided endocarditis |
|
ºñƯÀÌÀû Áõ»ó |
weakness, myalgia, dyspnea, chest pain, cough, headache, anorexia |
|
½Å°æÇÐÀû Áõ»ó |
30~40%(confusion, personality change, ÀÇ½Ä °¨¼Ò, ±¹¼ÒÀû ±Ù·Â ÀúÇÏ) |
|
vasculitic lesion |
petechiae |
nontender, not blanch with pressure
Á¡¸·°ú ÇǺο¡ Á¸Àç, Á¡¸·°ú °á¸·ÀÇ petechiae´Â pale center¸¦ °¡Áü |
|
splinter hemorrhage |
nail ¾Æ·¡¿¡¼ ¹ß°ß, nonspecific |
|
Osler¡¯s node |
painful, tender, erythematous nodule on palm surface of fingertip |
|
Janeway lesion |
nontender, erythematous, flat, macular lesion on palm and sole
blanch with pressure |
|
Ocular finding |
conjunctival or retinal hemorrhage
Roth¡¯s spots: pale center surrounded by a red halo |
 ±×¸² 1. Petechiae
 ±×¸² 2. Splinter hemorrhage (¼±»ó, Ãʱâ 2-3ÀÏÀº red, ÈÄ¿¡ brownish color)
 ±×¸² 3. Osler¡¯s node
 ±×¸² 4. Janeway lesion
Áø´Ü
Definition of major and minor criteria used in the Duke criteria
Duke criteria 1
|
Major criteria |
|
1. Ç÷¾×¹è¾ç°Ë»ç»ó ¾ç¼º |
|
1) 2°³ÀÇ ºÐ¸®µÈ Ç÷¾×¹è¾ç¿¡¼ ´ÙÀ½ÀÇ IE¿¡ ÇÕ´çÇÑ ÀüÇüÀûÀÎ microorganismÀÇ Á¸Àç*
(1) Streptococcus bovis, Viridans streptococci, HACEK group or
(2) Community-acquired Staphylococcus aureus or enterococci in the absence of a primary focus or
2) Áö¼ÓÀûÀÎ Ç÷¾×¹è¾ç ¾ç¼º¿¡¼ IE¿¡ ÇÕ´çÇÑ microorganismÀÇ Á¤ÀÇ
(1) >12½Ã°£ °£°ÝÀ¸·Î äÃëÇÑ Ç÷¾×¹è¾ç¿¡¼ Àû¾îµµ 2°³°¡ ¾ç¼º
(2) óÀ½°ú ¸¶Áö¸· äÃë°¡ Àû¾îµµ 12½Ã°£ °£°ÝÀ» µÐ 3°³ÀÇ Ç÷¾×¹è¾ç¿¡¼ ¾ç¼º ¶Ç´Â 4°³ÀÌ»óÀÇ Ç÷¾×¹è¾ç¿¡¼ ´ëºÎºÐÀÌ ¾ç¼º |
|
2. ½É³»¸· ħ¹üÀÇ Áõ°Å |
|
1) ½ÉÃÊÀ½ÆÄ»ó ¾ç¼º
(1) intracardiac mass: ÆÇ¸·À̳ª ÁöÁöÇÏ´Â ±¸Á¶¹°ÀÇ regurgitant jets°¡ ÀÖ´Â Åë·Î¿¡ oscillating intracardiac massÀÇ Á¸Àç, ¶Ç´Â ÇØºÎÇÐÀû º¯È°¡ ¾ø´Â ÀÌ½Ä ±¸Á¶¹°¿¡ oscillating intracardiac massÀÇ Á¸Àç
(2) ³ó¾ç
(3) ÀΰøÆÇ¸·ÀÇ »õ·Î ¹ß»ýÇÑ ºÎºÐÀûÀÎ dehiscence
2) »õ·Î ¹ß»ýÇÑ ÆÇ¸· ¿ª·ù(±âÁ¸ÀÇ ½ÉÀâÀ½ÀÇ ¾Çȳª º¯È´Â ºÒÃæºÐ) |
|
Minor criteria |
|
1. À¯¹ßÀÎÀÚ |
|
¼±ÇàÇÏ´Â ½ÉÀåÀÇ »óųª IV drug user |
|
2. ¹ß¿ |
|
ü¿Â> 38¡É |
|
3. Vascular phenomena |
|
major arterial emboli, septic pulmonary conjunctival hemorrhage, Janeway lesions |
|
4. Immunologic phenomena |
|
glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor |
|
5. Microbiologic evidence |
|
Ç÷¾×¹è¾ç ¾ç¼ºÀ̳ª Major criteria¿¡ ÇÕ´çÇÏÁö ¾Ê°Å³ª, IE¿¡ ÇÕ´çÇÑ microorganismÀÇ Çö°¨¿°À» ³ªÅ¸³»´Â Ç÷ûÇÐÀû Áõ°Å°¡ ÀÖ´Â °æ¿ì |
|
6. ½ÉÃÊÀ½ÆÄ ¼Ò°ß |
|
IE¿¡ ºÎÇյdzª major criteria¿¡ ¼ÓÇÏÁö ¾Ê´Â ¼Ò°ß |
* Coagulase negative staphylococci, IE¸¦ ÀÏÀ¸Å°Áö ¾Ê´Â organismÀÇ °æ¿ì 1°³ÀÇ Ç÷¾×¹è¾ç ¾ç¼ºµµ ÀÇÀǰ¡ ÀÖÀ½
Definitions of IE according to Duke criteria
Duke criteria 2
|
Definite infective endocarditis |
|
1. º´¸®ÇÐÀû ±âÁØ
1) vegetationÀÇ ¹è¾ç, Á¶Á÷ÇÐÀû °Ë»ç, »öÀüµÈ vegetation, ½ÉÀå³» ³ó¾ç¿¡¼ microorganisÀÇ Áõ¸í
2) vegetationÀ̳ª ½ÉÀå³» ³ó¾ç¿¡¼ Á¶Á÷ÇÐÀûÀ¸·Î active endocarditis¸¦ º¸ÀÌ´Â °æ¿ì
2. ÀÓ»óÀû ±âÁØ
1) 2°³ÀÇ major criteria
2) 1°³ÀÇ major criteria plus 3°³ÀÇ minor criteria
3) 5°³ÀÇ minor criteria |
|
Possible infective endocarditis |
|
Definite¿Í rejected »çÀÌ |
|
Rejected |
|
1. ´Ù¸¥ Áø´ÜÀÌ ºÙ¿©Áø °æ¿ì
2. 4ÀÏ À̳»ÀÇ Ç×»ýÁ¦ Ä¡·áÈÄ Áõ»óÀÇ ¼Ò½Ç
3. 4ÀÏ À̳»ÀÇ Ç×»ýÁ¦ Ä¡·áÈÄ ¼ö¼úÀ̳ª autopsy»ó¿¡¼ º´¸®ÇÐÀû Áõ°Å°¡ ¾ø´Â °æ¿ì |
Áø´ÜÀû °Ë»ç
|
°Ë»çÇ׸ñ |
¼³¸í |
|
bacteremiaÀÇ Æò°¡ |
Ç÷¾×¹è¾ç |
1. Ç×»ýÁ¦ »ç¿ë ½ÃÀÛ Àü¿¡ ½ÃÇà
2. ¼·Î ´Ù¸¥ 3°÷¿¡¼ ½ÃÇà, Ç×»ýÁ¦°¡ ½ÃÀÛµÈ °æ¿ì Ãß°¡·Î ½ÃÇà
3. óÀ½°ú ¸¶Áö¸· äÃë°¡ ÃÖ¼Ò 1½Ã°£Àº °£°ÝÀ» µÎ¾î¾ß ÇÔ
4. ÃÖ¼Ò 10cc¸¦ äÃë
5. Àü½ÅÀû ÇÕº´ÁõÀÌ Àְųª, »óŰ¡ ³ª»Ú°Ô º¸ÀÌ´Â °æ¿ì Ç×»ýÁ¦¸¦ ¹Ù·Î ½ÃÀÛ |
|
PCR |
|
|
ÀÓ»óº´¸® °Ë»ç |
1. ºóÇ÷
2. ESRÀÇ »ó½Â
3. Ç÷´¢ |
|
½ÉÀüµµ |
Áß¿äÇÑ ÀüµµÀå¾Ö: °¨¿°ÀÇ È®»êÀ» ÀǹÌÇÑ´Ù. |
|
CXR |
ÇÕº´ÁõÀ» ÆÄ¾Ç |
|
½ÉÃÊÀ½ÆÄ |
TTE |
first choice of imaging for native valves(ÁÁÀº ¿µ»óÀ» ¾òÀ» ¼ö ÀÖ´Â °æ¿ì) |
|
TEE |
1. sensitivity, specificity°¡ TTE¿¡ ºñÇØ ÁÁÀ¸³ª, ħ½ÀÀû °Ë»çÀ̰í skillÀ» ¿äÇÔ
2. ÀûÀÀÁõ
1) prosthetic valve¸¦ °¡Áø ȯÀÚ
2) TTE¿¡¼ image°¡ ÁÁÁö ¾ÊÀº ȯÀÚ
3) ÀÓ»óÀûÀ¸·Î Áߵ-°íµµ·Î IE°¡ ÀǽɵǴ ȯÀÚ |
Ä¡·á
|
Ä¡·á |
¼¼ºÎ»çÇ× |
|
Ãʱ⠾ÈÁ¤È |
1. È£Èí ºÎÀü: ±âµµÈ®º¸, ±â°èÈ£Èí
2. acute cardiac decompensation; ÁÖ·Î ÁÂÃøÀÇ ÆÇ¸· ºÎÀü
-> afterload °¨¼Ò½ÃÅ´, IABPÀû¿ë(aortic valve ruptureÀÇ °æ¿ì ±Ý±â) |
|
°æÇèÀû Ç×»ýÁ¦ Ä¡·á |
uncomplicated history |
|
1. ceftriaxone(1~2g IV) plus gentamycin(1~3mg/kg IV)
2. nafcillin(2g IV) plus gentamycin |
|
IV drug user, congenital heart disease, hospital acquired, suspected MRSA, ÀÌ¹Ì °æ±¸ Ç×»ýÁ¦ Ä¡·á¸¦ ¹ÞÀº °æ¿ì |
|
nafcillin(2g IV) plus gentamycin(1~3mg/kg IV) plus vancomycin(15mg/kg IV) |
|
prosthetic valve |
|
vancomycin(15mg/kg IV) plus gentamycin(1~3mg/kg IV) plus rifampin(300mg PO) |
|
È®Á¤µÈ Ç×»ýÁ¦ Ä¡·á |
¹è¾ç°Ë»ç¿Í sensitivity¿¡ µû¶ó¼ ½ÃÇà, 4~6ÁÖ°£ÀÇ Ä¡·á°¡ ÇÊ¿ä |
|
¼ö¼úÀû óġ |
ÀûÀÀÁõ
1. ½ÉÇÑ ÆÇ¸· ºÎÀüÀÌ ÀÖ´Â °æ¿ì
2. impaired hemodynamic status¸¦ º¸ÀÌ´Â °æ¿ì
3. relapsing prosthetic valve endocarditis
4. major embolic complication
5. fungal endocarditis
6. °¨¿°À¸·Î ÀÎÇØ ¹ß»ýÇÑ »õ·Î¿î ÀüµµÀå¾Ö
7. ÀûÀýÇÑ Ç×»ýÁ¦ Ä¡·á¿¡µµ ºÒ±¸Çϰí Áö¼ÓµÇ´Â bacteremia
* Å« vegetationÀÌ ¼ö¼úÀÇ ÀûÀÀÁõÀº ¾Æ´Ô |
|
Ç×ÀÀ°í Ä¡·á |
1. native valve endocarditis: not beneficial
2. ±âÁ¸ÀÇ Ç×ÀÀ°í Ä¡·á¸¦ ¹Þ¾Ò´ø prosthetic valveȯÀÚ: ÁÖÀÇ ±í°Ô À¯Áö |
¿¹¹æ
Prophylaxis°¡ ÇÊ¿äÇÑ ´ë»ó
½É³»¸·¿° ¿¹¹æ ´ë»ó
|
Prophylaxis°¡ ÇÊ¿äÇÑ ´ë»ó |
½Ã¼ú |
|
1. porsthetic heart valves
2. congenital cardiac malformations
3. acquired valvular dysfunction
4. HCMP
5. MVP with documented regurgitation
6. history of endocarditis |
1. dental work(including cleaning)
2. bronchoscopy
3. cystoscopy
4. urethral instrumentation
5. ERCP
|
* MVP without regurgitation, pacemaker, physiologic murmur, prior CABG or angioplasty, previous surgical repair of ASD, VSD, PDA- not routinely recommend * local injection, laceration suturing, IV line placement, blood drawing, endotracheal intubation, endoscopy, vaginal delivery, urethral catheterization, uterine D&C- not indicated
Prophylaxis against endocarditis for high risk patients
½É³»¸·¿° ¿¹¹æ¹ý
|
½Ã¼ú |
Ç×»ýÁ¦ |
¿ë·® |
|
Ä¡°ú/±¸°/È£Èí±â/½Äµµ ½Ã¼ú |
Amoxicillin
or Ampicillin
or Clindamycin
or Azithromycin |
2g PO(½Ã¼ú 1½Ã°£Àü)
2g IM or IV(½Ã¼ú 30ºÐÀü)
600mg PO(½Ã¼ú 1½Ã°£Àü) ¶Ç´Â 600mg IV(½Ã¼ú 30ºÐÀü)
500mg PO(½Ã¼ú 1½Ã°£Àü) |
|
ºñ´¢»ý½Ä±â°è/¼Òȱâ°è ½Ã¼ú |
1. ½Ã¼ú 30ºÐÀü: Ampicillin(2g IM ¶Ç´Â IV) plus gentamycin(1.5mg/kg IM ¶Ç´Â IV)
-> ½Ã¼ú 6½Ã°£ ÈÄ¿¡ ampicillin(1g IM ¶Ç´Â IV) ¶Ç´Â amoxicillin(1g PO)
2. Vancomycin(½Ã·ê 30ºÐÀü ±îÁö, 1~2½Ã°£¿¡ °ÉÃÄ 1gÀ» IV) plus gentamycin(½Ã¼ú 30ºÐÀ̳»¿¡ 1.5mg/kg IV ¶Ç´Â IM) |
|